Organovo, an early-stage medical laboratory and research company, is set to merge with Tarveda Therapeutics, a privately-held, clinical-stage biopharmaceutical company. Financial terms were not disclosed. “We are disappointed that we will be unable to proceed with the planned transaction with Organovo. While surprised by the late decision of Organovo’s major stockholders to vote against the recommendation of Organovo’s special committee with the apparent intent to pursue a strategy which may include 3D bioprinting, we respect their decision,” Drew Fromkin, Tarveda Chief Executive Officer. Organovo announced the termination of a merger agreement with Tarveda Therapeutics on April 7, 2020.